Cancer Immunotherapy in China: Communicating With Your Home Medical Team

What the two teams actually need from each other

A handover is not a single email. It is a defined exchange in which each side knows what it is being asked to do. Your home medical team holds the longitudinal picture: the original diagnosis, how the cancer has behaved over time, which treatments have already been given, and what toxicities or complications occurred. The China team holds the assessment question: whether a specific immunotherapy approach is appropriate for your tumour type and stage, and whether it can be delivered here.

The practical mistake is sending a large unlabelled archive and assuming the receiving clinician will find the relevant parts. A better approach is to send a short cover summary plus a clearly indexed set of documents. The cover summary states the diagnosis in plain terms, the current question, and what you want back. The indexed documents let the China clinician verify rather than guess.

Immunotherapy helps the immune system act against cancer, and whether it is appropriate depends on the cancer and individual assessment. That single sentence explains why the exchange must be specific. "Can I have immunotherapy?" is not answerable without the tumour type, the biomarker context and the treatment history. "For this diagnosis, with these prior treatments and this biomarker result, is immunotherapy appropriate, and if so what would the monitoring plan be?" is a question a clinician can actually address.

The records that make the question answerable

Start with the pathology. The China team needs the original pathology report, not only a summary letter. If biomarker testing was performed, the report that states which markers were tested and what the results were is more useful than a second-hand note saying "biomarker positive". If testing was not performed, that absence is itself important information, because it changes what can be assessed remotely.

Next, the treatment history. A chronological list of prior therapies, with dates, agents, response and reason for stopping, gives the China clinician the context to judge whether an immunotherapy option is plausible. Include prior immunotherapy if any, and any immune-related adverse events, because these affect how a future plan would be framed.

Then the current status. Recent imaging reports, the most recent clinical note, current medications and relevant blood results help the team understand where you are now. You do not need to send everything at once. A short summary first, then the specific documents the team requests, is usually more workable than a complete archive in the first message.

Finally, the question you want answered. Write it down in one or two sentences. If your home team has already given an opinion, include it. The China team should know what your home clinicians think, not be asked to assess in isolation.

• Pathology report stating tumour type and any biomarker results, or a note that testing was not done.
• Chronological treatment list: agents, dates, response, reason for stopping, and any immune-related side effects.
• Recent imaging reports and the latest clinical note.
• Current medications and relevant recent blood results.
• Your written question, plus any opinion your home team has already given.

What to ask the China team to send back

The return leg matters as much as the outbound one. Ask the China team to provide a written assessment that your home clinicians can read and act on. That document should state the tumour type and stage as the China team understands them, whether immunotherapy is considered appropriate and on what basis, what alternatives were considered, and what monitoring would be needed.

Ask specifically how monitoring would continue at home. Immunotherapy can require periodic assessment, and your home team needs to know what the China team recommends observing and on what schedule. Do not assume the two teams will coordinate automatically. Name the person or department on each side who will receive and send information.

If the China team's view differs from your home team's, ask for the reasoning in writing. A changed recommendation is only useful if the basis is clear: new records, a different interpretation of the pathology, or a different reading of the biomarker result. Without that, your home team cannot evaluate the change.

Ask what remains uncertain. A records-based opinion has limits, and a responsible clinician should be able to say what cannot be concluded without an in-person assessment. That is not a weakness in the opinion; it is information you need before deciding whether to travel.

Questions that belong to each side

Some questions are for the China hospital, and some are for your home team. Keeping them separate prevents confusion. The China hospital decides whether immunotherapy is appropriate for your diagnosis, what regimen would be considered, what pre-treatment assessment is needed, and whether the service is available for your case. Those are clinical and institutional decisions, and no coordination service can make them on the hospital's behalf.

Your home team decides how follow-up continues locally: who will see you, what monitoring can be arranged, and how any treatment given abroad would be integrated into your ongoing care. Ask your home oncologist directly whether they are willing to receive and act on a plan from China, and what they would need in order to do so.

Practical questions sit between the two. Ask the named China provider what its written estimate includes, what records it still needs, and how it communicates with clinicians abroad. Ask your home team what documentation it requires for its own records. Do not assume either side's administrative process; confirm it.

How to keep the exchange moving

Set a single point of contact on each side. A named person on your home team and a named contact at the China hospital reduce the chance that messages stall. Confirm who will translate clinical documents if needed, and whether the translation is done by a qualified medical translator rather than a general service.

Keep a simple log: what was sent, to whom, on what date, and what reply is expected. This is not bureaucracy; it is how you notice that a pathology report was never received or that a question was answered only in part.

If a reply is preliminary, treat it as preliminary. A first response may say that more records are needed before an opinion can be given. That changes your next action: send the missing item rather than booking travel. If a reply confirms that an appointment can be requested, that is still not the same as confirmed hospital acceptance or treatment availability.

Do not interrupt or delay current treatment to pursue an overseas enquiry. If your symptoms worsen, local urgent care takes priority. An overseas assessment is a parallel process, not a reason to pause necessary care.

Where ChinaSpecialistCare fits, and the next step

ChinaSpecialistCare provides information and non-clinical coordination. We can help you organise records into a clear summary, arrange interpretation, and request a specialist appointment at a suitable hospital. We do not prescribe, decide suitability, or promise that a treatment is available. The hospital makes those decisions.

If you want help with the handover, start with a free initial enquiry. Send a brief summary of the diagnosis, the main question, and what records you already have. Our team will identify what is missing and suggest the relevant next step. You do not need to buy a proxy consultation to make an initial enquiry, and you should not send passport numbers, card details or a complete medical archive at this stage.

For more detail on how immunotherapy is assessed and planned in China, see the Cancer Immunotherapy reference page. The most useful thing you can do now is write your one-sentence question and list the records that answer it.

Related treatment reference